Growth • Denali Therapeutics
DNLI
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
0%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
0%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
0%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!